管理多病患者

Iain Wilkinson, Joanna Preston
{"title":"管理多病患者","authors":"Iain Wilkinson,&nbsp;Joanna Preston","doi":"10.1016/j.intcar.2021.100045","DOIUrl":null,"url":null,"abstract":"<div><p><span>Multimorbidity is associated with advancing age and </span>frailty<span> states. Those with multimorbidity are more likely to have increased morbidity and mortality as well as care needs. Polypharmacy<span> can be problematic in this group with attention required to determine what is appropriate and what is problematic. A distinct approach is necessary to manage multi-morbidity, compared with single organ management. Awareness is required of the relative paucity of evidence-based medicine in this area due to the heterogeneity of combinations of conditions and individual circumstances. Decisions should be made in partnership with the patient living with these conditions and include a dialogue regarding likely benefits and risks of existing management strategies alongside their goals. This article suggests a five step approach to this in the clinic setting. 1) Discussing the purpose of taking multimorbidity specific approach, 2) Establishing disease and treatment burdens, 3) Establishing goals, values and priorities, 4) Review of medications and other treatment and finally 5) Agree an individualized management plan.</span></span></p></div>","PeriodicalId":100283,"journal":{"name":"Clinics in Integrated Care","volume":"5 ","pages":"Article 100045"},"PeriodicalIF":0.0000,"publicationDate":"2021-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.intcar.2021.100045","citationCount":"0","resultStr":"{\"title\":\"Managing patients with multimorbidity\",\"authors\":\"Iain Wilkinson,&nbsp;Joanna Preston\",\"doi\":\"10.1016/j.intcar.2021.100045\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p><span>Multimorbidity is associated with advancing age and </span>frailty<span> states. Those with multimorbidity are more likely to have increased morbidity and mortality as well as care needs. Polypharmacy<span> can be problematic in this group with attention required to determine what is appropriate and what is problematic. A distinct approach is necessary to manage multi-morbidity, compared with single organ management. Awareness is required of the relative paucity of evidence-based medicine in this area due to the heterogeneity of combinations of conditions and individual circumstances. Decisions should be made in partnership with the patient living with these conditions and include a dialogue regarding likely benefits and risks of existing management strategies alongside their goals. This article suggests a five step approach to this in the clinic setting. 1) Discussing the purpose of taking multimorbidity specific approach, 2) Establishing disease and treatment burdens, 3) Establishing goals, values and priorities, 4) Review of medications and other treatment and finally 5) Agree an individualized management plan.</span></span></p></div>\",\"PeriodicalId\":100283,\"journal\":{\"name\":\"Clinics in Integrated Care\",\"volume\":\"5 \",\"pages\":\"Article 100045\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-04-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1016/j.intcar.2021.100045\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinics in Integrated Care\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2666869621000117\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinics in Integrated Care","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666869621000117","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

多病与年龄增长和身体虚弱有关。那些患有多种疾病的人更有可能增加发病率和死亡率以及护理需求。在这个群体中,多重用药可能是有问题的,需要注意确定什么是合适的,什么是有问题的。与单器官治疗相比,多器官治疗需要不同的方法。由于条件组合和个人情况的异质性,需要认识到这一领域循证医学的相对缺乏。决策应与患有这些疾病的患者合作,并包括就现有管理策略的可能益处和风险以及其目标进行对话。本文建议在临床环境中采取五步方法。1)讨论采取多病特异性方法的目的,2)确定疾病和治疗负担,3)确定目标,价值观和优先事项,4)回顾药物和其他治疗,最后5)商定个体化管理计划。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Managing patients with multimorbidity

Multimorbidity is associated with advancing age and frailty states. Those with multimorbidity are more likely to have increased morbidity and mortality as well as care needs. Polypharmacy can be problematic in this group with attention required to determine what is appropriate and what is problematic. A distinct approach is necessary to manage multi-morbidity, compared with single organ management. Awareness is required of the relative paucity of evidence-based medicine in this area due to the heterogeneity of combinations of conditions and individual circumstances. Decisions should be made in partnership with the patient living with these conditions and include a dialogue regarding likely benefits and risks of existing management strategies alongside their goals. This article suggests a five step approach to this in the clinic setting. 1) Discussing the purpose of taking multimorbidity specific approach, 2) Establishing disease and treatment burdens, 3) Establishing goals, values and priorities, 4) Review of medications and other treatment and finally 5) Agree an individualized management plan.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信